Russian Military Medical Academy ReportsRussian Military Medical Academy Reports2713-23152713-2323Eco-Vector4337710.17816/rmmar43377Research ArticleDIAGNOSTIC SIGNIFICANCE OF THE PROSTATIC SPECIFIC ANTIGEN AND THE VOLUME OF THE PROSTATE GLAND IN DETERMINING THE CHARACTER OF THE PATHOLOGICAL PROCESSMagomedovZ. M-PiltoyanD. A-S.M. Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation151220202S110410728082020Copyright © 2020, Magomedov Z.M., Piltoyan D.A.2020Oncological diseases in the world take the second place in mortality after cardiovascular pathology. In recent decades, experts have noted an increase in the occurrence of prostate tumors among men around the world. Tumors are most often represented by benign hyperplasia and cancer. One of the main criteria for identifying these pathologies in the male population is the level of specific prostatic specific antigen in serum. Currently, a specific prostatic antigen is widely used in the diagnosis of cancer and benign prostatic hyperplasia, establishing the stage of the process, and evaluating the effectiveness of treatment. The aim of the work is to assess the diagnostic significance of the level of specific prostatic antigen and volume in determining the nature of the pathology of the prostate gland. As the study are patients of the Clinic of Urology of S.M. Kirov Military Medical Academy with diseases of the prostate gland. Studied: age, the nature of the pathology, the level of the specific prostatic specific antigen of blood serum, the volume of the prostate gland. The data obtained showed: the average age of the patients was 69 years; among the studied in 42% of cases diagnosed with prostate cancer, in 58% of cases - benign hyperplasia; in all subjects, the level of this marker and the volume of the prostate are higher than normal (average values are 12,1 ng/ml and 65,2 cm , respectively). The results of this study showed that, having organ-specificity, a specific prostatic antigen and prostate volume are not differential diagnostic criteria for the pathological process. Diagnosis of diseases of the prostate gland should be carried out taking into account a complex of data from clinical, laboratory, radiation and morphological studies.prostatic specific antigenprostate cancertumor-specific markerbenign prostatic hyperplasiaпростатический специфический антигенрак предстательной железыопухолево-специфический маркердоброкачественная гиперплазия предстательной железы[1. Протощак, В.В. Иммунологические аспекты диагностики рака предстательной железы / В.В. Протощак [и др.] // Вестник урологии. - 2018. - №6 (4). - С.42-48.][2. Пушкарь, Д.Ю. Дифференциальная диагностика рака и доброкачественной гиперплазии предстательной железы / Д.Ю. Пушкарь, П.И. Раснер // Русский медицинский журнал. Библиотека пациента. Урология. - 2017. - №18. - С.58-60.][3. Чиссов, В.И. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / В.И. Чиссов, В.В. Старинский, Г.В. Петрова // Медицинский журнал. - 2009. - 244 с.][4. Каприн, А.Д. Диагностика и лечение ранних форм рака предстательной железы / А.Д. Каприн // Вопросы онкологии. - 2018. - №3. - С.382-385.][5. Сергеева, Н.С. Роль простатспецифического антигена в диагностике и мониторинге больных раком предстательной железы: Пособие для врачей / Н.С. Сергеева, И.Г. Русаков, М.П. Мишунина. - 2018. - С.28-35.][6. Тимофеева, А.В. Оценка диагностической значимости общего простат-специфического антигена в качестве маркера развития опухолей предстательной железы / А.В.Тимофеева, Е.В. Мальковская А.Л. Бурмистрова // Проблемы современной науки и образования. - 2015. - С.42-48.][7. Ilic, D. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis / D. Ilic [et al.] // Br. Med. - 2018. - P.18-42.][8. Colloca, G. Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review / G. Colloca // Cancer Treat. Rev. - 2019. - P. 32-56.]